Filtered By:
Condition: Pain
Cancer: Hepatocellular Carcinoma
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1075 results found since Jan 2013.
FDA Approval Summary: Tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma
Clin Cancer Res. 2023 Sep 7. doi: 10.1158/1078-0432.CCR-23-2124. Online ahead of print.ABSTRACTOn October 21, 2022, the FDA approved tremelimumab (Imjudo) in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (uHC). The approval was based on the results from the HIMALAYA study, in which patients with uHC who were naïve to previous systemic treatment were randomized to receive one of three study arms: tremelimumab in combination with durvalumab (n=393), durvalumab (n=389), or sorafenib (n=389). The primary objective of improvement in overall survival (OS) for tremelimumab in combinati...
Source: Clinical Cancer Research - September 7, 2023 Category: Cancer & Oncology Authors: Timil H Patel Jamie R Brewer Jiaxin Fan Joyce Cheng Yuan Li Shen Yue Xiang Hong Zhao Steven J Lemery Richard Pazdur Paul G Kluetz Lola A Fashoyin-Aje Source Type: research
Low back pain as an atypical presentation of hepatocellular carcinoma: A case report
Asian J Surg. 2023 Aug 16:S1015-9584(23)01220-4. doi: 10.1016/j.asjsur.2023.08.017. Online ahead of print.NO ABSTRACTPMID:37596212 | DOI:10.1016/j.asjsur.2023.08.017
Source: Asian Journal of Surgery - August 18, 2023 Category: Surgery Authors: Renjian He Yu Fan Jiran Deng Quping Yang Source Type: research
Effect of music therapy on postembolization syndrome in Thai patients with hepatocellular carcinoma: A quasi-experimental crossover study
CONCLUSION: Music therapy effectively reduces mild pain among patients with liver cancer experiencing PES. This therapy can be used as a non-pharmacological treatment for nurses and other healthcare professionals in caring for patients with liver cancer.PMID:37554492 | PMC:PMC10405647 | DOI:10.33546/bnj.2210
Source: Cancer Control - August 9, 2023 Category: Cancer & Oncology Authors: Wassana Khuntee Kanitha Hanprasitkam Bualuang Sumdaengrit Source Type: research
Incidence and predictors of abdominal pain after transarterial chemoembolization of hepatocellular carcinoma: a single-center retrospective study
CONCLUSION: The model suggests that DEB-TACE and multiple treatment sites are predictors of abdominal pain after TACE in patients with hepatocellular carcinoma. It may help improve nursing management practices.PMID:37524027 | DOI:10.1016/j.ejon.2023.102355
Source: European Journal of Oncology Nursing - July 31, 2023 Category: Nursing Authors: Qian-Qian Du Min Liang Bo Jiang Miao Zhang Xiao-Ling Yu Xiao Li Jia-Hu Hao Source Type: research
Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature
This study aims to present a comprehensive overview of fibrolamellar carcinoma (FLC), with a focus on its epidemiology, pathogenesis, diagnosis, treatment, and prognosis. FLC frequently incorporate features of stomach pain, weight loss, and malaise in their clinical signs and symptoms, which are generally nonspecific Ultimately, the most common physical finding is an abdominal mass or hepatomegaly. With this said, several unusual presentations have been documented such as Budd Chiari syndrome, severe anaemia, non-bacterial thrombotic endocarditis and many more. In regards to this tumour's genetic analysis, it is characteri...
Source: Pathology, Research and Practice - July 10, 2023 Category: Pathology Authors: Yasir Alshareefy Chai Yu Shen Rosheene Jeya Prekash Source Type: research
The parotid gland, an unusual site of colorectal cancer metastasis
We present a case of stage IV sigmoid colon adenocarcinoma with metastases to the left parotid. The patient was a 53-year-old Filipino man diagnosed with stage IV sigmoid adenocarcinoma with liver metastases in June 2021. He underwent laparoscopic sigmoidectomy and received eight cycles of chemotherapy with capecitabine and oxaliplatin with partial response of his liver lesions. Capecitabine monotherapy was then maintained. On September 2022, he experienced persistent left facial pain, with no relief after dental tooth extraction and antibiotics. A computed tomography (CT) scan revealed a 5 × 7 × 6 cm inhomogenous mass i...
Source: Cancer Control - July 3, 2023 Category: Cancer & Oncology Authors: Paula Isabel G Francoa Anna Pascual-Panganiban Source Type: research
New aryl and acylsulfonamides as state-dependent inhibitors of Na < sub > v < /sub > 1.3 voltage-gated sodium channel
Eur J Med Chem. 2023 Jun 9;258:115530. doi: 10.1016/j.ejmech.2023.115530. Online ahead of print.ABSTRACTVoltage-gated sodium channels (Navs) play an essential role in neurotransmission, and their dysfunction is often a cause of various neurological disorders. The Nav1.3 isoform is found in the CNS and upregulated after injury in the periphery, but its role in human physiology has not yet been fully elucidated. Reports suggest that selective Nav1.3 inhibitors could be used as novel therapeutics to treat pain or neurodevelopmental disorders. Few selective inhibitors of this channel are known in the literature. In this work, ...
Source: European Journal of Medicinal Chemistry - June 17, 2023 Category: Chemistry Authors: Nace Zidar Tihomir Toma šič Danijel Kikelj Martina Durcik Jan Tytgat Steve Peigneur Marc Rogers Alexander Haworth Robert W Kirby Source Type: research
Impact of Quality Control Circle on Patient Outcomes after Hepatocellular Carcinoma Intervention: A Meta-Analysis
CONCLUSIONS: QCC after HCC intervention can reduce postoperative fever, nausea and vomiting, abdominal pain, and loss of appetite. It also improves patient knowledge of health education and satisfaction with care.PMID:37313599 | DOI:10.1080/14737140.2023.2219899
Source: Expert Review of Anticancer Therapy - June 14, 2023 Category: Cancer & Oncology Authors: Yimin Wang Yuerong Lai Wenzhen Shen Li Du Source Type: research
